05.07.2022 18:13

Top Analyst Reports for Novo Nordisk, Intel & Qualcomm

Folgen
Werbung
Tuesday, July 5, 2022 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Intel Corp. (INTC), and Qualcomm Inc. (QCOM). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today’s research reports here >>>Novo Nordisk shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+32.6% vs. +20.1%) on the back of the company’s promising diabetes drug, Ozempic. The Zacks analyst has described the Rybelsus launch as further strengthening Novo Nordisk's best-in-class diabetes portfolio. Ozempic, Rybelsus, Xultophy and Saxenda have been helping the company maintain momentum. Label expansion of these existing drugs is expected to boost sales. However, lower realized prices in the U.S., loss of exclusivity for products and stiff competition are affecting sales totals. Patent expiration on some of the products in Novo Nordisk’s portfolio is a concern. Sales continue to be negatively impacted by the Covid pandemic. Supply challenges for Wegovy have also hurt the stock.(You can read the full research report on Novo Nordisk here >>>)Intel shares have declined -28.3% year to date versus the Zacks Semiconductor - General industry’s decline of -41.6%. The chip-making major reaffirmed its earlier guidance for 2022 despite short-term headwinds, as it expects demand to pick up in the second half of the year. The company is riding on prospects of the Internet of Things and Mobileye businesses. Mobileye growth should be driven by design wins amid a recovering auto industry. Recovery in the enterprise business of the data center segment is a positive. Intel is developing more integrated solutions that will likely be competitive on a cost-per-watt basis while offering customized solutions for bigger firms.(You can read the full research report on Intel here >>>)Qualcomm shares have declined -10.9% over the past year against the Zacks Wireless Equipment industry’s decline of -16.7%. The company faces intense competition from low-cost chip manufacturers. High research and development costs are expected to dent margins, while the global chip shortage due to supply-chain disruptions is a headwind. It is susceptible to risks arising from lower handset shipments, especially in China.However, Qualcomm is focused on retaining its leadership in 5G and the chipset market, delivering low-power resilient multi-gigabit connectivity with best-in-class security. It is witnessing healthy traction in EDGE networking solutions across diverse sectors. The buyout of Arriver will bolster its ability to deliver fully integrated Advanced Driver Assistance System solutions to automakers. The company is well-positioned to benefit from solid 5G traction with greater visibility and diversified businesses to meet its long-term revenue targets.(You can read the full research report on Qcom here >>>)Other noteworthy reports we are featuring today include T-Mobile US, Inc. (TMUS), Blackstone Inc. (BX), and Sony Group Corp. (SONY). Mark VickerySenior Editor Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>Today's Must ReadNovo Nordisk (NVO) Rides High on Robust Diabetes Drugs SalesIntel (INTC) Rides on Diversified Portfolio, Holistic GrowthQualcomm (QCOM) Rides on 5G Traction, Portfolio StrengthFeatured ReportsSONY to Gain from Brand Focus & Improving G&NS Segment SalesPer the Zacks analyst, Sony's focus on the premium segment of the branded products market to boost growth is a tailwind. The company expects G&NS Segment sales to be driven by higher hardware sales.Business Model Revamp Aids Mitsubishi (MUFG), Costs AilPer the Zacks analyst, Mitsubishi UFJ's up-gradation and reformation of its business model will improve profitability. Yet, higher salaries are likely to inflate costs and impede bottom-line growth.TC Energy's (TRP) C$24B Growth Projects to Boost EarningsThe Zacks analyst believes that TC Energy's C$24 billion of growth projects should support its earnings and dividend payouts but is worried over the massive debt of around C37 billion.Favorable Budget Aids L3Harris (LHX), Poor Air Travel WoesPer the Zacks analyst, increased budgetary provision for defense spending boost growth prospects for L3Harris Technologies. Yet poor air travel data may continue to hurt the stock.AutoZone (AZO) Gains on DIY Unit, Revenue, Supply Woes HurtPer the Zacks analyst, AutoZone's DIY unit is reaping profits. Its impressive revenues fuel long-term prospects. But, supply chain issues along with chip crisis are likely to clip margins and growth.Solid Liquidity Aids Paychex (PAYX) Despite Talent Cost WoesThe Zacks analyst is optimistic about Paychex's gradual increase in current ratio and investor-friendly steps. However, rising talent costs due to competition are a headwind.Fastenal (FAST) Gains From E-Commerce, Inflation HurtsPer the Zacks analyst, continued enhancement of daily sales through e-commerce will drive Fastenal's growth. However, inflationary pressures, tight supply chains and labor shortages are risks.New UpgradesT-Mobile (TMUS) Likely to Benefit From Extensive 5G CoveragePer the Zacks analyst, T-Mobile remains poised to gain from extensive 5G coverage and improved 5G Home Internet services across the country and has raised the guidance for 2022 across the board.Blackstone (BX) Poised for Asset Growth Driven by InflowsPer the Zacks analyst, continued net inflows will keep aiding Blackstone's assets under management. Its diversified products and superiority in the alternative investments space will support top line.Pediatrix Medical's (MD) Strategic Buyouts, Telehealth AidPer the Zacks analyst, Pediatrix Medical's strategic acquisitions boost its footprint and service offerings across markets. Also, its expanding telehealth services will continue driving profits.New DowngradesRenaissanceRe (RNR) Continues to Grapple With High Cat LossPer the Zacks analyst, the property & casualty (P&C) insurer remains susceptible to several catastrophic events, which impact its underwriting results. Higher expenses are woes.Rising Costs, Supply-Chain Issues Irk Tandem Diabetes (TNDM)The Zacks analyst is concerned about Tandem Diabetes' escalating operating expenses which are weighing on its bottom line. Global supply-chain headwinds also continue challenge the company.Soft Garden Segment to Hurt Central Garden's (CENT) SalesPer the Zacks analyst, tough operating environment and softness in the Garden portfolio are likely to hurt Central Garden & Pet Company's sales. As a result, management cut fiscal 2022 earnings view.Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intel Corporation (INTC): Free Stock Analysis Report Blackstone Inc. (BX): Free Stock Analysis Report QUALCOMM Incorporated (QCOM): Free Stock Analysis Report Novo Nordisk AS (NVO): Free Stock Analysis Report TMobile US, Inc. (TMUS): Free Stock Analysis Report Sony Corporation (SONY): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Weiter zum vollständigen Artikel bei "Zacks"
Ausgewählte Hebelprodukte auf Intel Corp.
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Intel Corp.
Long
Short
Hebel wählen:
5x
10x
Name
Hebel
KO
Emittent
Quelle: Zacks

Nachrichten zu Intel Corp.

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Intel Corp.

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
01.08.2022Intel OutperformCredit Suisse Group
29.07.2022Intel UnderperformBernstein Research
29.07.2022Intel SellGoldman Sachs Group Inc.
25.07.2022Intel UnderperformBernstein Research
19.07.2022Intel UnderperformBernstein Research
01.08.2022Intel OutperformCredit Suisse Group
29.04.2022Intel OutperformCredit Suisse Group
15.02.2022Intel OutperformCredit Suisse Group
27.01.2022Intel OverweightJP Morgan Chase & Co.
27.01.2022Intel OutperformCredit Suisse Group
18.02.2022Intel NeutralUBS AG
18.02.2022Intel HoldDeutsche Bank AG
15.02.2022Intel NeutralUBS AG
27.01.2022Intel NeutralUBS AG
07.12.2021Intel Equal-weightMorgan Stanley
29.07.2022Intel UnderperformBernstein Research
29.07.2022Intel SellGoldman Sachs Group Inc.
25.07.2022Intel UnderperformBernstein Research
19.07.2022Intel UnderperformBernstein Research
11.07.2022Intel UnderweightBarclays Capital

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Intel Corp. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Werbung
Werbung
Werbung
Neue Funktionen als Erstes nutzen
Sie nutzen finanzen.net regelmäßig? Dann nutzen Sie jetzt neue Funktionen als Erstes!
Hier informieren!
Werbung
Börse Stuttgart Anlegerclub
Werbung

Heute im Fokus

DAX wenig bewegt -- Henkel im ersten Halbjahr mit Gewinnrückgang -- HelloFresh profitiert vom US-Geschäft -- Nordex bestätigt trotz Verlust Jahresprognose -- ENCAVIS, Deutsche Telekom im Fokus

Lufthansa: Ärger bei Tochter Eurowings Discover. Salzgitter setzt für den Fall von Gasrationierung für sich auf Ausnahmeregelungen. Fehlende Scheinwerfer bereiten Porsche Probleme. Gasumlage beträgt 2,4 Cent pro Kilowattstunde. Studie: DAX-Konzerne mit guten Geschäften - Rekordumsatz im Quartal. Malaysia Airlines erneuert Flotte mit dem A330neo.

Umfrage

Sollten die Corona-Regeln bei steigenden Infektionszahlen im Herbst wieder verschärft werden?

finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln